Diabetes Is Not For The Faint Of Heart
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Regulatory and commercial hurdles in the type 2 diabetes market have created a space where only the largest, most sophisticated companies can expect to compete.
You may also be interested in...
Merck And Pfizer Make A Late Play For The Diabetes Market
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.
In A Changing Diabetes Drug Market, Who Will Come Out On Top?
New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.
Bragg Live Wants Consumers To Know Efficacy Differs Among Apple Cider Vinegar Formats
Bragg Live says its survey highlights misconceptions consumers have concerning health benefits and efficacy of different delivery formats of apple cider vinegar.